CoChat

Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study

Bone, Henry G., Lindsay, Robert, McClung, Michael R., Perez, Alfonso T., Raanan, Marsha G., Spanheimer, Robert G. · 2013 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Abstract

CONTEXT: Meta-analyses of clinical studies have suggested an increased incidence of peripheral fractures in postmenopausal women with type 2 diabetes mellitus taking pioglitazone. The mechanism behind this apparent increase is unknown. OBJECTIVE: The objective of the study was to examine the effects of pioglitazone on bone mineral density (BMD) and turnover. DESIGN AND SETTING: Twenty-five sites (in the United States) enrolled participants in this randomized, double-blind, placebo-controlled study. PARTICIPANTS: Postmenopausal women (n = 156) with impaired fasting glucose or impaired glucose tolerance participated in the study. INTERVENTIONS: The intervention consisted of pioglitazone 30 mg/d (n = 78) or placebo (n = 78), increased to 45 mg/d after 1 month, for 12 months of treatment total, followed by 6 months of washout/follow-up. MAIN OUTCOME MEASURES: Percentage changes from baseline to month 12 and from month 12 to month18 in BMD in total proximal femur (primary end point), total body, femoral neck, lumbar spine, and radius were measured. RESULTS: Least squares mean changes from baseline to month 12 in total proximal femur BMD were -0.69% for pioglitazone and -0.14% for placebo (P = .170). No statistically significant between-group differences were observed for any BMD or bone remodeling marker end point. We observed improved glycemic control and insulin sensitivity with pioglitazone treatment. In addition, pioglitazone appeared to increase body fat, which may affect bone density measurements, especially in the lumbar spine. One pioglitazone-treated and three placebo-treated women experienced confirmed fractures. Over 18 months, one pioglitazone-treated (1.3%) and eight placebo-treated women (10.3%) developed overt type 2 diabetes mellitus. The pattern and incidence of adverse events with pioglitazone were consistent with clinical experience with thiazolidinediones. CONCLUSIONS: Maximal-dose pioglitazone had no effects on BMD or bone turnover, while improving glycemic control as expected, in postmenopausal women with impaired fasting glucose or impaired glucose tolerance.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2012-4096

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Cited by

See all 48

Metadata

Authors
Bone, H. G., Lindsay, R., McClung, M. R., Perez, A. T., Raanan, M. G., & Spanheimer, R. G.
Affiliations
  • Helen Hayes Hospital (US)
  • Takeda (United States) (US)
Corresponding author
Bone, Henry G.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2013-12
Volume
98
Issue
12
Pages
4691-4701
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2085155826
Cited by
47
References
53
Citations by year
2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 6 · 2016: 8 · 2015: 8 · 2014: 8 · 2013: 2
FWCI
8.87
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Research Bank (Australian Catholic University) (submittedVersion)
Funders
  • Amgen
  • Eli Lilly and Company
  • Takeda Pharmaceuticals North America
  • Takeda Pharmaceuticals International
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
thiazolidinediones, bone mineral density, bone turnover, postmenopausal women, impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, fracture, glycemic control, insulin sensitivity, fat mass, lumbar spine
MeSH terms
Pioglitazone, Aged, Bone and Bones, Bone Resorption, Double-Blind Method, Female, Follow-Up Studies, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin Resistance, Middle Aged, Prediabetic State, Biomarkers, Bone Density, Bone Remodeling, Postmenopause, Glucose Intolerance, Thiazolidinediones, Adiposity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1210/jc.2012-4096
The paper
Bone, H. G., Lindsay, R., McClung, M. R., Perez, A. T., Raanan, M. G., & Spanheimer, R. G. (2013). Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2012-4096

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.